Vertex Pharmaceuticals Incorporated (VRTX) - Financial and Strategic SWOT Analysis Review

Date: March 15, 2016
Pages: 66
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V6A67E08D94EN
Leaflet:

Download PDF Leaflet

Vertex Pharmaceuticals Incorporated (VRTX) - Financial and Strategic SWOT Analysis Review
Vertex Pharmaceuticals Incorporated (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Vertex Pharmaceuticals Incorporated (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of small molecule drugs for the treatment of serious and life-threatening ailments. The company offers Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of patients with cystic fibrosis (CF). The company’s research and development efforts focus on influenza and bacterial infections, inflammatory diseases, cancer, neurological diseases and disorders including pain, and cystic fibrosis. The company develops several pipeline products for the treatment of cystic fibrosis, oncology, pain and influenza. It has operations in the US, the UK, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Incorporated Key Recent Developments

Feb 24, 2016: Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Jan 27, 2016: Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
Jan 10, 2016: Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
Nov 23, 2015: Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
Oct 30, 2015: Vertex Pharma Provides Update On DOJ Subpoena

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Vertex Pharmaceuticals Incorporated - Key Facts
Vertex Pharmaceuticals Incorporated - Key Employees
Vertex Pharmaceuticals Incorporated - Key Employee Biographies
Vertex Pharmaceuticals Incorporated - Major Products and Services
Vertex Pharmaceuticals Incorporated - Pharmaceutical Pipeline Products Data
Vertex Pharmaceuticals Incorporated, Pipeline Products by Therapy Area
Vertex Pharmaceuticals Incorporated, Pipeline Products by Development Phase
Vertex Pharmaceuticals Incorporated - History
Vertex Pharmaceuticals Incorporated - Company Statement
Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Vertex Pharmaceuticals Incorporated - Business Description
Vertex Pharmaceuticals Incorporated - Corporate Strategy
Vertex Pharmaceuticals Incorporated - SWOT Analysis
SWOT Analysis - Overview
Vertex Pharmaceuticals Incorporated - Strengths
Strength - Intellectual Property
Strength - Operational Network
Strength - Lead Product: Kalydeco (ivacaftor)
Vertex Pharmaceuticals Incorporated - Weaknesses
Weakness - Withdrawal of Incivek from the US Market
Weakness - Higher Cost Structure
Vertex Pharmaceuticals Incorporated - Opportunities
Opportunity - Market Potential: HCV
Opportunity - Market Potential: Cystic Fibrosis
Opportunity - Pipeline Products
Vertex Pharmaceuticals Incorporated - Threats
Threat - Competitive Market
Threat - Patent Expiry
Threat - Stringent Government Regulations
Vertex Pharmaceuticals Incorporated - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, OIL & GAS FINANCIAL DEALS AND ALLIANCES

Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Vertex Pharmaceuticals Incorporated, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 24, 2016: Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis
Jan 27, 2016: Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results
Jan 10, 2016: Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
Nov 23, 2015: Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer
Oct 30, 2015: Vertex Pharma Provides Update On DOJ Subpoena
Oct 28, 2015: Vertex Reports Third Quarter 2015 Financial Results
Jul 29, 2015: Vertex Reports Second Quarter 2015 Financial Results
Jun 18, 2015: Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
Jun 12, 2015: Vertex Pharmaceuticals announces board change
Apr 29, 2015: Vertex Reports First Quarter 2015 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Vertex Pharmaceuticals Incorporated, Key Facts
Vertex Pharmaceuticals Incorporated, Key Employees
Vertex Pharmaceuticals Incorporated, Key Employee Biographies
Vertex Pharmaceuticals Incorporated, Major Products and Services
Vertex Pharmaceuticals Incorporated, Number of Pipeline Products by Therapy Area
Vertex Pharmaceuticals Incorporated, Number of Pipeline Products by Development Stage
Vertex Pharmaceuticals Incorporated, Pipeline Products By Therapy Area and Development Phase
Vertex Pharmaceuticals Incorporated, History
Vertex Pharmaceuticals Incorporated, Other Locations
Vertex Pharmaceuticals Incorporated, Subsidiaries
Vertex Pharmaceuticals Incorporated, Key Competitors
Vertex Pharmaceuticals Incorporated, Ratios based on current share price
Vertex Pharmaceuticals Incorporated, Annual Ratios
Vertex Pharmaceuticals Incorporated, Interim Ratios
Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Vertex Pharmaceuticals Incorporated, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Vertex Pharmaceuticals Incorporated, Pipeline Products by Therapy Area
Vertex Pharmaceuticals Incorporated, Pipeline Products by Development Phase
Vertex Pharmaceuticals Incorporated, Performance Chart (2011 - 2015)
Vertex Pharmaceuticals Incorporated, Ratio Charts
Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Vertex Pharmaceuticals Incorporated, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Vertex Pharmaceuticals Incorporated (VRTX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: